AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30981000 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals (controls)
Number of subjects: 32
Study 30981008 — intervention group
Group type: EXPERIMENTAL
Intervention: MINI index scores below 8 in the derivation cohort
Number of subjects: 322
Study 30981008 — intervention group
Group type: EXPERIMENTAL
Intervention: MINI index scores below 8 in the validation cohort
Number of subjects: 322
Study 30981008 — intervention group
Group type: EXPERIMENTAL
Intervention: MINI index scores of 8 or more in the validation cohort
Number of subjects: 322
Study 30981008 — intervention group
Group type: EXPERIMENTAL
Intervention: MINI index scores below 8
Number of subjects: 322
Study 30981008 — intervention group
Group type: EXPERIMENTAL
Intervention: MINI index scores below 6
Number of subjects: 322
Study 30981008 — intervention group
Group type: COMPARATOR
Intervention: Measurement of fecal calprotectin
Number of subjects: 322
Study 30981280 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term ureteral stenting (3-6 weeks)
Number of subjects: 0
Study 30981280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral stent biofilms
Number of subjects: 0
Study 30981280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial communities in biofilms
Number of subjects: 0
Study 30981280 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of extracellular DNA
Number of subjects: 0
Study 30981280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral stent biofilms in patients with Enterobacterales and Corynebacterium-dominated microbiomes
Number of subjects: 0
Study 30981280 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification of patients according to different urotypes
Number of subjects: 0
Study 30981280 — intervention group
Group type: EXPERIMENTAL
Intervention: Facultative pathogens
Number of subjects: 0
Study 30981574 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high-risk features (n=5323)
Number of subjects: 10236
Study 30981574 — intervention group
Group type: COMPARATOR
Intervention: Patients without high-risk features
Number of subjects: 10236
Study 30981574 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with increasing number of high-risk features (0, 1-2, ≥3)
Number of subjects: 10236
Study 30981574 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with high-PRECISE-DAPT score (≥25)
Number of subjects: 10236
Study 30981717 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional introital ultrasound imaging
Number of subjects: 250
Study 30981717 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional transperineal ultrasound imaging
Number of subjects: 250
Study 30981717 — intervention group
Group type: COMPARATOR
Intervention: Endoanal ultrasound imaging
Number of subjects: 250
Study 30981717 — intervention group
Group type: EXPERIMENTAL
Intervention: Introital and transperineal ultrasound imaging
Number of subjects: 250
Study 30981722 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal mobility on presentation and first recorded NEWS < 3
Number of subjects: 3363
Study 30981722 — intervention group
Group type: EXPERIMENTAL
Intervention: IMOP and NEWS ≥ 3 when first recorded
Number of subjects: 3363
Study 30981722 — intervention group
Group type: EXPERIMENTAL
Intervention: IMOP
Number of subjects: 3363
Study 30981722 — intervention group
Group type: EXPERIMENTAL
Intervention: NEWS ≥ 3 when first recorded
Number of subjects: 3363
Study 30981783 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentiviral vector-derived gene therapy
Number of subjects: 8
Study 30981956 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular long naps
Number of subjects: 4170
Study 30981956 — intervention group
Group type: COMPARATOR
Intervention: Regular short naps, irregular naps, or no naps
Number of subjects: 4170
Study 30981987 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ctDNA analysis
Number of subjects: 192
Study 30981987 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA assay
Number of subjects: 192
Study 30981987 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA assay for lung cancer stages
Number of subjects: 192
Study 30981987 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ctDNA, patient age, and serum biomarkers
Number of subjects: 192
Study 30982000 — intervention group
Group type: EXPERIMENTAL
Intervention: All-site screening for CT/NG infections
Number of subjects: 764
Study 30982000 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal screening
Number of subjects: 764
Study 30982000 — intervention group
Group type: COMPARATOR
Intervention: Single anatomical site testing
Number of subjects: 764
Study 30982000 — intervention group
Group type: COMPARATOR
Intervention: Pharyngeal site testing
Number of subjects: 764
Study 30982000 — intervention group
Group type: COMPARATOR
Intervention: Rectal site testing
Number of subjects: 764
Study 30982000 — intervention group
Group type: COMPARATOR
Intervention: Urethral site testing
Number of subjects: 764
Study 30982564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative low-dose fentanyl (about 60-120 μg for a 70 kg patient)
Number of subjects: 145735
Study 30982564 — intervention group
Group type: COMPARATOR
Intervention: High intraoperative fentanyl doses (median: 3.85; IQR: 3.42-4.50 μg kg)
Number of subjects: 145735
Study 30982564 — intervention group
Group type: COMPARATOR
Intervention: No fentanyl
Number of subjects: 145735
Study 30982671 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day strategy (hour h, h+1, h+2)
Number of subjects: 131
Study 30982671 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy (sputum collection on three consecutive days)
Number of subjects: 131
Study 30982671 — intervention group
Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 131
Study 30982856 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's own milk (MOM), n = 74, average 91% MOM in enteral feeds.
Number of subjects: 125
Study 30982856 — intervention group
Group type: COMPARATOR
Intervention: Donor breast milk (DM), n = 43, average 14% MOM in enteral feeds.
Number of subjects: 125
Study 30983543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal glucose load
Number of subjects: 0
Study 30984044 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 0
Study 30984044 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30984354 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily walnut intake (45 g for 16 weeks)
Number of subjects: 119
Study 30984354 — intervention group
Group type: COMPARATOR
Intervention: Iso-caloric white bread (control)
Number of subjects: 119
Study 30984405 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based lifestyle behavior intervention study
Number of subjects: 569
Study 30984879 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional bundle to reduce mortality from gastroschisis
Number of subjects: 0
Study 30984970 — intervention group
Group type: EXPERIMENTAL
Intervention: High systolic home BP variability
Number of subjects: 75
Study 30984970 — intervention group
Group type: COMPARATOR
Intervention: Low systolic home BP variability
Number of subjects: 75
Study 30984970 — intervention group
Group type: EXPERIMENTAL
Intervention: Home BP variability
Number of subjects: 75
Study 30985279 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost treatment via the Breelib nebulizer for 3 months ± 2 weeks, in addition to existing PAH therapy.
Number of subjects: 80
Study 30985279 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost treatment via the Breelib nebulizer.
Number of subjects: 80
Study 30985286 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring in addition to prenatal follow-up
Number of subjects: 91
Study 30985369 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fat transfer (AFT); average volume: 23.9 ± 13.2 mL
Number of subjects: 20
Study 30985509 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 605
Study 30985509 — intervention group
Group type: COMPARATOR
Intervention: Standard indications (SI)
Number of subjects: 605
Study 30985509 — intervention group
Group type: COMPARATOR
Intervention: Complex medical disorders
Number of subjects: 605
Study 30985509 — intervention group
Group type: COMPARATOR
Intervention: NMD vs SI
Number of subjects: 605
Study 30985509 — intervention group
Group type: COMPARATOR
Intervention: NMD vs Complex medical disorders
Number of subjects: 605
Study 30985509 — intervention group
Group type: COMPARATOR
Intervention: Severe infantile onset NMD vs general hypotonic disorders
Number of subjects: 605
Study 30986359 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridge-enhanced ACL repair with extracellular matrix scaffold
Number of subjects: 62
Study 30986523 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate empirical antibiotic therapy (IEAT)
Number of subjects: 729
Study 30986523 — intervention group
Group type: COMPARATOR
Intervention: Healthcare-associated infection (HCAI)
Number of subjects: 729
Study 30986523 — intervention group
Group type: COMPARATOR
Intervention: Hospital-acquired infection (HAI)
Number of subjects: 729
Study 30986523 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate empirical antibiotic therapy (IEAT) in bloodstream infections
Number of subjects: 729
Study 30986548 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing instability
Number of subjects: 340
Study 30986735 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 591052
Study 30986735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood stabilizing anticonvulsants (MSAs)
Number of subjects: 591052
Study 30986735 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 591052
Study 30986735 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors (MAOIs)
Number of subjects: 591052
Study 30986735 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 591052
Study 30986735 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (combination of drugs)
Number of subjects: 591052
Study 30986735 — intervention group
Group type: COMPARATOR
Intervention: No drug
Number of subjects: 591052
Study 30986750 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital statins
Number of subjects: 6523
Study 30986750 — intervention group
Group type: COMPARATOR
Intervention: No prehospital statins (Control)
Number of subjects: 6523
Study 30986750 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy at discharge
Number of subjects: 6523
Study 30986750 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate doses of statins at discharge
Number of subjects: 6523
Study 30987448 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CCM having TTN truncating variants (TTNtvs)
Number of subjects: 213
Study 30987448 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CCM with TTNtvs
Number of subjects: 213
Study 30987448 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-treated TTNtv mice and isolated TTNtv cardiomyocytes
Number of subjects: 213
Study 30987597 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml albumin 5% administered over 1 min in three consecutive 50-ml fluid boluses, followed by an additional 350 ml infused at a constant rate over 15 min (total 500 ml)
Number of subjects: 50
Study 30988080 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose lapatinib (1,500 mg BID)
Number of subjects: 11
Study 30988080 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-dose lapatinib alternating with capecitabine
Number of subjects: 11
Study 30988172 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI Access assay measured at presentation and at 1 hour
Number of subjects: 1579
Study 30988172 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnI Architect assay
Number of subjects: 1579
Study 30988677 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 30988677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30989318 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR levels in the highest quartile
Number of subjects: 1314
Study 30989318 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR levels
Number of subjects: 1314
Study 30989318 — intervention group
Group type: EXPERIMENTAL
Intervention: suPAR
Number of subjects: 1314
Study 30989318 — intervention group
Group type: COMPARATOR
Intervention: GRACE score
Number of subjects: 1314
Study 30989318 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of suPAR to GRACE score
Number of subjects: 1314
Study 30989436 — intervention group
Group type: EXPERIMENTAL
Intervention: Various anti-glioblastoma agents including temozolomide, carmustine, lomustine, procarbazine, irinotecan, cediranib, erlotinib, 5-fluorouracil, vincristine, dichloroacetate, IDH1 inhibitor ivosidenib; treatment duration: 3 or 6 days
Number of subjects: 6
Study 30989436 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 6
Study 30990523 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% IV infusion of glucose during exercise
Number of subjects: 2
Study 30990523 — intervention group
Group type: COMPARATOR
Intervention: Healthy persons
Number of subjects: 2
Study 30990523 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient 1 (male, 26 years old)
Number of subjects: 2
Study 30990523 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient 2 (female, 15 years old)
Number of subjects: 2
Study 30991108 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30991107 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated GLP-1 levels at 24 hours
Number of subjects: 157
Study 30991107 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistently elevated GLP-1 levels at day 14
Number of subjects: 157
Study 30991107 — intervention group
Group type: COMPARATOR
Intervention: Overall inpatient mortality
Number of subjects: 157
Study 30991107 — intervention group
Group type: COMPARATOR
Intervention: Post-discharge 6-month mortality
Number of subjects: 157
Study 30991107 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 and IL-6 levels
Number of subjects: 157
Study 30991107 — intervention group
Group type: COMPARATOR
Intervention: Early death (<14 days)
Number of subjects: 157
Study 30991623 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurovascular biomarkers in T2DM patients
Number of subjects: 0
Study 30991623 — intervention group
Group type: EXPERIMENTAL
Intervention: ALFF-CBF in left hippocampus and fractional ALFF-CBF in left amygdala
Number of subjects: 0
Study 30991623 — intervention group
Group type: EXPERIMENTAL
Intervention: ALFF-CBF in right fusiform gyrus
Number of subjects: 0
Study 30991623 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 0
Study 30991623 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of T2DM
Number of subjects: 0
Study 30991692 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor cells (CTCs)
Number of subjects: 34
Study 30991823 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Cardiac Resynchronization Therapy
Number of subjects: 0
Study 30991823 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30991908 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation plus automated text messaging intervention (iTAB-CV) for 2 months
Number of subjects: 38
Study 30991908 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation plus automated text messaging intervention (iTAB-CV)
Number of subjects: 38
Study 30991949 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated ultrasound spinal landmark identification technique
Number of subjects: 100
Study 30991972 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week habit-focused intervention (telecoaching and face-to-face sessions)
Number of subjects: 24
Study 30991992 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (50 mg intravenously once daily during first induction chemotherapy)
Number of subjects: 65
Study 30991992 — intervention group
Group type: COMPARATOR
Intervention: Micafungin
Number of subjects: 65
Study 30992008 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit fasting plasma glucose (FPG) variability (measured by coefficient of variation, CV-FPG)
Number of subjects: 455
Study 30992054 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional P-V curves derived from electrical impedance tomography (EIT)
Number of subjects: 12
Study 30992054 — intervention group
Group type: COMPARATOR
Intervention: Global P-V curves (PVg)
Number of subjects: 12
Study 30992268 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG) 150 mg daily for 24 weeks
Number of subjects: 40
Study 30992268 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG) 150 mg daily
Number of subjects: 40
Study 30992268 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined long-term data from both studies
Number of subjects: 40
Study 30992268 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted deep sequencing/whole-exome sequencing pre-EPAG and at primary response end point
Number of subjects: 40
Study 30993165 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cholangioscopy
Number of subjects: 0
Study 30993165 — intervention group
Group type: COMPARATOR
Intervention: Occlusion cholangiogram
Number of subjects: 0
Study 30993521 — intervention group
Group type: EXPERIMENTAL
Intervention: Less invasive unilateral posterolateral disc space debridement, supplemented by ipsilateral titanium cage implantation and pedicle screw fixation plus contralateral transfascial pedicle screw fixation
Number of subjects: 20
Study 30994466 — intervention group
Group type: EXPERIMENTAL
Intervention: Dignity Therapy (DT) led by nurses or chaplains
Number of subjects: 560
Study 30994466 — intervention group
Group type: COMPARATOR
Intervention: Usual outpatient palliative care
Number of subjects: 560
Study 30994471 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEveCOPD computer application
Number of subjects: 0
Study 30994825 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual anti-platelet therapy (DAPT)
Number of subjects: 0
Study 30994825 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 30994825 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 30994826 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 0
Study 30994826 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical treatment
Number of subjects: 0
Study 30994826 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional treatment
Number of subjects: 0
Study 30995146 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-clot treatment scale
Number of subjects: 0
Study 30995146 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment satisfaction questionnaire for medication version II
Number of subjects: 0
Study 30995208 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin 15 mg·kg infused over 1 hour, repeated every 12 hours
Number of subjects: 20
Study 30995208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 30 mg·kg infused over 10 minutes, repeated every 4 hours
Number of subjects: 20
Study 30995331 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 300
Study 30995372 — intervention group
Group type: EXPERIMENTAL
Intervention: Lentiviral vector gene therapy combined with low-dose busulfan conditioning
Number of subjects: 8
Study 30995373 — intervention group
Group type: EXPERIMENTAL
Intervention: UB-421 (10 mg/kg weekly)
Number of subjects: 29
Study 30995373 — intervention group
Group type: EXPERIMENTAL
Intervention: UB-421 (25 mg/kg every 2 weeks)
Number of subjects: 29
Study 30996012 — intervention group
Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg orally twice weekly on days 1 and 3 of each week, three of each 4-week cycle
Number of subjects: 10
Study 30997117 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Number of subjects: 40
Study 30997151 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept plus methotrexate
Number of subjects: 124
Study 30997151 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 124
Study 30997151 — intervention group
Group type: COMPARATOR
Intervention: Abatacept
Number of subjects: 124
Study 30997507 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Energy Density (LED) preload (33 kcal/100 g)
Number of subjects: 31
Study 30997507 — intervention group
Group type: COMPARATOR
Intervention: High Energy Density (HED) preload (97.9 kcal/100 g)
Number of subjects: 31
Study 30997633 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 26
Study 30997633 — intervention group
Group type: EXPERIMENTAL
Intervention: NOL index
Number of subjects: 26
Study 30998220 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging (SMS)-based distance learning program
Number of subjects: 48
Study 30998393 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent implantation in African American women (AA)
Number of subjects: 1863
Study 30998393 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent implantation in Hispanic/Latina women (HL)
Number of subjects: 1863
Study 30998393 — intervention group
Group type: COMPARATOR
Intervention: White women (reference group)
Number of subjects: 1863
Study 30998529 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR)
Number of subjects: 0
Study 30998529 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR) followed with exercise
Number of subjects: 0
Study 30998529 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study 30998789 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF with or without 3TC or FTC (n = 489)
Number of subjects: 1419
Study 30998789 — intervention group
Group type: COMPARATOR
Intervention: 3TC or FTC only (n = 150)
Number of subjects: 1419
Study 30998789 — intervention group
Group type: EXPERIMENTAL
Intervention: 3TC or FTC as first line followed by adding/switching to TDF as second line (n = 780)
Number of subjects: 1419
Study 30999262 — intervention group
Group type: EXPERIMENTAL
Intervention: Online social intelligence training (SIT) program
Number of subjects: 230
Study 30999262 — intervention group
Group type: COMPARATOR
Intervention: Attention-control (AC) condition
Number of subjects: 230
Study 30999906 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythritol candies
Number of subjects: 90